Humanigen, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cameron Durrant MBA
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 830 Morris Turnpike Short Hills NJ United States of America 07078-2625
- IPO Date
- Jan 31, 2013
- CIK
- 0001293310
- Website
- humanigen.com
- Similar Companies
- Business
- Humanigen, Inc. (Nasdaq: HGEN) is a clinical-stage biopharmaceutical company that develops proprietary monoclonal antibodies and therapies targeting immune hyper-responses, cytokine storms, and rare diseases including respiratory conditions, hematologic cancers, and parasitic infections; its lead product candidates comprise lenzilumab (LENZ), a first-in-class antibody neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) for cytokine storm in COVID-19, CD19-targeted CAR-T therapies, chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), acute graft-versus-host disease, eosinophilic asthma, and rheumatoid arthritis, alongside ifabotuzumab targeting EphA3 for oncological applications in tumor vasculature and myelodysplastic syndromes, and benznidazole for Chagas disease treatment in the U.S. The company, founded in 2017 and headquartered at 1000 Marina Boulevard, Suite 250, Brisbane, California, operates primarily in the biotechnology sector with a focus on North American and select international markets including the United Kingdom, European Union countries, and India where lenzilumab is available via compassionate use and LenzMAP programs. In recent developments, Humanigen filed for Chapter 11 bankruptcy protection on January 3, 2024, in the U.S. Bankruptcy Court for the District of Delaware following delisting from Nasdaq in October 2023 and challenges from denied FDA approval for lenzilumab in COVID-19; its key assets including lenzilumab, ifabotuzumab, related clinical data, and intellectual property were sold to Taran Therapeutics, Inc., a entity led by former CEO Dr. Cameron Durrant, with the transaction approved by the court on February 14, 2024, and closed shortly thereafter to enable continued development of these compounds.
US says former Humanigen chief scientific officer charged with insider trading
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy
Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy
Why Is Humanigen (HGEN) Stock Down 72% Today?
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
3 Hot Penny Stocks To Watch Today; Is It Time To Buy?
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
Humanigen Reports Third Quarter 2022 Financial Results
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Humanigen Announces Retention of SC&H Capital as Financial Advisor
HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
HGEN DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Humanigen Investors of a Lead Plaintiff Deadline of October 25, 2022